E2MATE For Treating Endometriosis

Risk of prostate cancer in two age groups base...

Risk of prostate cancer in two age groups based on Free PSA as % of Total PSA Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A, Richie J, deKernion J, Walsh P, Scardino P, Lange P, Subong E, Parson R, Gasior G, Loveland K, Southwick P (1998). “Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial”. JAMA 279 (19) : 1542–7. doi:10.1001/jama.279.19.1542. PMID 9605898. (Photo credit: Wikipedia)

Endometriosis is a gynecological disorder. Tens of millions around the world suffer from this painful ailment where there is an overgrowth in the lining of the uterus, the endometrium.

A drug has been tested at the University of Bath. It has passed the critical clinical trial and it looks promising. This drug, E2MATE (PGL2001), is a product of the Medicinal Chemistry Group at the Pharmacy and Pharmacology Department of the University. It has been used in Phase 2 cancer treatments before. But it now seems to be useful for treating the non-cancerous Endometriosis.

Following the E2MATE’s promising clinical trial, the research is now on a 2008 paper published from the efforts of the University of Bath and London’s Imperial College. The drug they looked at is called Irosustat.

Professor Barry Potter headed up the two research teams. He is pleased with the results that all their hard work yielded. He notes that only a few drugs investigated as new treatments show promising results in their trials. But with E2MATE, he can see the drug going far.

Preglem, a pharmaceutical company, conducted the trials but Sterix Ltd., co-founded by Potter, owns the formulation and the study behind E2MATE. An overview of the research about Endometriosis Treatment appeared in the Reproductive Sciences journal.

E2MATE For Treating Endometriosis by
Rating: 4.5. From 1 vote.
Please wait...
Share/Bookmark
Share/Bookmark
%d bloggers like this: